Pterygium of the Conjunctiva and CorneaNCT07343011
Conjunctival Transpositional Surgery for Primary Pterygium
A study testing Conjunctival Transpositional Pterygium Surgery in people with Pterygium of the Conjunctiva and Cornea, run by Zahedan University of Medical Sciences at 1 site in Iran.
Trial summary
This prospective single-arm interventional study evaluates the recurrence rate and functional outcomes following conjunctival transpositional pterygium surgery without bare sclera formation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pterygium of the Conjunctiva and Cornea
- What is being tested?
- Conjunctival Transpositional Pterygium Surgery
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteIran
- Study dates
- 21 May 2025to 1 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older
- Primary pterygium involving the cornea
- Ability to provide informed consent
Who cannot join
- Recurrent pterygium
- Previous ocular surface surgery
- Active ocular infection or inflammation
- Severe ocular surface disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Iran1 site, 1 recruiting
- Recruiting
Alzahra Eye Hospital, Zahedan University of Medical Sciences
Zahedan, Sistan and Balochistan
Mohammed Arish, MD, FRCS, 09151419155, mohammad.erish@zaums.ac.ir
About this study
Official title: Conjunctival Transpositional Pterygium Surgery: A Prospective Single-Arm Interventional Study
This prospective single-arm interventional study evaluates the recurrence rate and functional outcomes following conjunctival transpositional pterygium surgery without bare sclera formation. The technique involves mobilization and transposition of the pterygium tissue while preserving Tenon's layer and avoiding adjunctive therapies.
- Conditions
- Pterygium of the Conjunctiva and Cornea
- Being tested
- Conjunctival Transpositional Pterygium Surgery
- Medical subject headings
- Corneal Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Conjunctival Transpositional Pterygium SurgeryProcedure or surgery
A conjunctival incision was created at the upper and lower limbus to allow adequate tissue mobilization. The pterygium tissue is dissected off the corneal surface without complete excision or creation of a bare sclera defect. The fibrovascular tissue is mobilized and transposed inferiorly within the subconjunctival plane and secured with absorbable sutures. Tenon's tissue is preserved, and no adjunctive therapy is used.
| Study group | Role | What they receive |
|---|---|---|
| Pterygium patients | Experimental | Not described Receives: Procedure: Conjunctival Transpositional Pterygium Surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pterygium Recurrence
Recurrence is defined as fibrovascular regrowth toward the cornea or surgical failure.
Measured: 12 months
Secondary outcomes (2)
Visual Acuity
Change in visual acuity measured in logMAR units.
Measured: 12 months
Refractive Astigmatism
Change in refractive astigmatism measured as cylindrical power in diopters.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2026
- Study start21 May 2025
- Primary completion1 May 2026 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pterygium of the Conjunctiva and CorneaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zahedan University of Medical Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohammed Arish, Zahedan University of Medical Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07343011
- Sponsor's protocol ID
- IR.ZAUMS.REC.1404.238
- Status last verified
- Jan 2026
- First submitted
- 6 Jan 2026
- Last updated
- 15 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Conjunctival Transpositional Pterygium Surgery: A Prospective Single-Arm Interventional Study
- ClinicalTrials.gov ID
- NCT07343011
- Acronym / sponsor ID
- IR.ZAUMS.REC.1404.238
- Conditions
- Pterygium of the Conjunctiva and Cornea
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Zahedan University of Medical SciencesUniversity, hospital or other
- Study start
- 21 May 2025 (actual)
- Primary completion
- 1 May 2026 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 15 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective single-arm interventional study evaluates the recurrence rate and functional outcomes following conjunctival transpositional pterygium surgery without bare sclera formation. The technique involves mobilization and transposition of the pterygium tissue while preserving Tenon's layer and avoiding adjunctive therapies.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pterygium patients | Experimental | Procedure: Conjunctival Transpositional Pterygium Surgery |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged 18 years or older
- Primary pterygium involving the cornea
- Ability to provide informed consent
Key exclusion criteria (4 listed)
- Recurrent pterygium
- Previous ocular surface surgery
- Active ocular infection or inflammation
- Severe ocular surface disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Conjunctival Transpositional Pterygium SurgeryA conjunctival incision was created at the upper and lower limbus to allow adequate tissue mobilization. The pterygium tissue is dissected off the corneal surface without complete excision or creation of a bare sclera defect. The fibrovascular tissue is mobilized and transposed inferiorly within the subconjunctival plane and secured with absorbable sutures. Tenon's tissue is preserved, and no adjunctive therapy is used. | Procedure or surgery | Pterygium patients |
Primary outcome
Pterygium Recurrence
Time frame: 12 months
Recurrence is defined as fibrovascular regrowth toward the cornea or surgical failure.
2 secondary outcomes
Visual Acuity
Time frame: 12 months
Refractive Astigmatism
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2026.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Conjunctival Transpositional Pterygium Surgery in people with Pterygium of the Conjunctiva and Cornea, run by Zahedan University of Medical Sciences at 1 site in Iran.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohammed Arish, MD, FRCS (09151419155, mohammad.erish@zaums.ac.ir), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pterygium Recurrence (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2026.